A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Table 4 The most common treatment-emergent adverse events for the overall study period (≥10.0% )

Abbreviations: BSC = best supportive care; TEAE = treatment-emergent adverse event.
^aThe most common TEAEs for the overall study period in the group of patients who were enrolled into the induction phase and who received at least 1 dose of study therapy. This includes the patients who were randomized into the maintenance phase (n = 55) and the patients who were not randomized (n = 51).
^bThe most common TEAEs during induction and maintenance therapy in the patients randomized to the maintenance phase arms.
^cConsidered to be study drug-related.
^dTwo (1.9%) patients experienced grade 3 or 4 drug-related fatigue.
^eOne (0.9%) patient experienced grade 3 or 4 drug-related decreased appetite.
^fSix (5.7%) patients in the all treated patient population and 1 (3.6%) randomized patient in the pemetrexed/BSC arm experienced drug-related grade 3 or 4 anemia.

ISSN: 1471-2407